#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Complex regional pain syndrome Carcinoid tumour Leukocyte adhesion deficiency type I Orthostatic hypotension Acute lymphocytic leukaemia Arteriovenous malformation Hereditary motor and sensory neuropathy Mitochondrial myopathy Haemophilia A with anti factor VIII Cutaneous lupus erythematosus Arrhythmia Cardiac sarcoidosis Antithrombin III deficiency Sjogren's syndrome Leukaemia More trials…

    Learn about Rare Diseases

    Langerhans cell sarcoma – Treatment Primary hyperoxaluria – Trials in Disease Gastrointestinal stromal tumour – Diagnostics Cytokine release syndrome – Life with Disease Rosai-Dorfman syndrome – Trials in Disease Angiosarcoma metastatic – Life with Disease Lymphangioma – Diagnostics Kearns-Sayre syndrome – Basic Information Extranodal marginal zone B-cell lymphoma (MALT type) – Life with Disease Short-bowel syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ocrelizumab SAR445399 ZALFERMIN SC0062 Golimumab Iron Tng462 Cefuroxime Axetil Semaglutide Levodropropizine Efgartigimod Alfa Ziclumeran Fosaprepitant Milvexian Sodium Acetate Trihydrate Englumafusp Alfa Ab-1002 ATIGOTATUG Prasinezumab Oxygen More therapies…

    Learn about Your Condition

    End stage renal disease Hypophosphatasia Skin ulcer Rectosigmoid cancer Psychotic behaviour Neuroendocrine carcinoma Gouty arthritis Demyelination Hip fracture PIK3CA-activated mutation Leukaemia Myocardial ischaemia Meningococcal infection Alcohol abuse Hyperoxaluria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Male Urogenital Diseases

  • Study on the Effect of Degarelix and Ultrasound Therapy for Patients with Intermediate-Risk Prostate Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Degarelix
    Finland

  • Study on Overactive Bladder Treatment for Women Using Clostridium Botulinum Neurotoxin Type A and Vibe System

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Hypertonic bladder
    Investigated Drugs:
    • Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
    Portugal

  • Study Comparing Docetaxel, Darolutamide, and ADT for Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Buserelin Acetate
    • Darolutamide
    • Leuprorelin Acetate
    Austria Germany

  • Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer recurrent
    Investigated Drugs:
    • Gallium (68Ga) Gozetotide
    • Piflufolastat (18F)
    • Darolutamide
    Austria Belgium Czechia Denmark Finland France +8

  • Study on Reduced BCG Dwell-Time for Patients with High-Risk Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Denmark Iceland Sweden

  • Study on the Effectiveness of Ipilimumab and Nivolumab for Patients with Bladder Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    The Netherlands
Previous Page
1 … 22 23 24 25
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!